RT Journal Article
SR Electronic
T1 Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 701
OP 702
DO 10.3899/jrheum.170151
VO 44
IS 5
A1 Kristina Callis Duffin
A1 Alice B. Gottlieb
A1 Joseph F. Merola
A1 John Latella
A1 Amit Garg
A1 April W. Armstrong
YR 2017
UL http://www.jrheum.org/content/44/5/701.abstract
AB The International Dermatology Outcome Measures (IDEOM) psoriasis working group was established to develop core domains and measurements sets for psoriasis clinical trials and ultimately clinical practice. At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, the IDEOM psoriasis group presented an overview of its progress toward developing this psoriasis core domain set. First, it summarized the February 2016 meeting of all involved with the IDEOM, highlighting patient and payer perspectives on outcome measures. Second, the group presented an overview of the consensus process for developing the core domain set for psoriasis, including previous literature reviews, nominal group exercises, and meeting discussions. Future plans include the development of working groups to review candidate measures for at least 2 of the domains, including primary pathophysiologic manifestations and patient-reported outcomes, and Delphi surveys to gain consensus on the final psoriasis core domain set.